Zingg, Daniel; Bhin, Jinhyuk; Yemelyanenko, Julia; Kas, Sjors M; Rolfs, Frank; Lutz, Catrin; Lee, Jessica K; Klarenbeek, Sjoerd; Silverman, Ian M; Annunziato, Stefano; Chan, Chang S; Piersma, Sander R; Eijkman, Timo; Badoux, Madelon; Gogola, Ewa; Siteur, Bjørn; Sprengers, Justin; de Klein, Bim; de Goeij-de Haas, Richard R; Riedlinger, Gregory M; ... (2022). Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature, 608(7923), pp. 609-617. Springer Nature 10.1038/s41586-022-05066-5 Zingg, D, Bhin, J, Yemelyanenko, J, Kas, S M, Rolfs, F, Lutz, C, Lee, J K, Klarenbeek, S, Silverman, I M, Annunziato, S, Chan, C S, Piersma, S R, Eijkman, T, Badoux, M, Gogola, E, Siteur, B, Sprengers, J, de Klein, B, de Goeij-de Haas, R R, Riedlinger, G M, Ke, H, Madison, R, Drenth, A P, van der Burg, E, Schut, E, Henneman, L, van Miltenburg, M H, Proost, N, Zhen, H, Wientjens, E, de Bruijn, R, de Ruiter, J R, Boon, U, de Korte-Grimmerink, R, van Gerwen, B, Féliz, L, Abou-Alfa, G K, Ross, J S, van de Ven, M, Rottenberg, S, Cuppen, E, Chessex, A V, Ali, S M, Burn, T C, Jimenez, C R, Ganesan, S, Wessels, L F A & Jonkers, J 2022, ' Truncated FGFR2 is a clinically actionable oncogene in multiple cancers ', Nature, vol. 608, no. 7923, pp. 609-617 . https://doi.org/10.1038/s41586-022-05066-5 Nature, 608(7923), 609-617. Nature Publishing Group